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Sebaceous gland neoplasias are the cutaneous manifes-
tation of the Muir^Torre syndrome, which is known to
be a phenotypical variant of hereditary nonpolyposis
colorectal cancer. Both hereditary nonpolyposis color-
ectal cancer and Muir^Torre syndrome are caused by
inherited DNA mismatch repair defects. As a promi-
nent molecular genetic feature, all tumors associated
with a DNA mismatch repair defect exhibit high mi-
crosatellite instability. So far, the frequency of DNA
mismatch repair defects in patients selected solely on
the basis of a sebaceous gland tumor has never been
determined. In order to estimate this frequency, we
assessed microsatellite instability with up to 10 microsa-
tellite markers in a newly collected unselected series of
25 sebaceous gland neoplasias (six sebaceous adenomas,
16 sebaceous epitheliomas, three sebaceous carcinomas)
in comparison to 32 sebaceous gland hyperplasias from
unrelated patients. As many as 15 of the 25 sebaceous
gland neoplasias (60%), but only one of the 32 sebaceous
gland hyperplasias (3%), exhibited high microsatellite
instability. Thus, in our study, the majority of patients
with a sebaceous gland neoplasia in contrast to patients
with a sebaceous gland hyperplasia are highly suspi-
cious for an inherited DNA mismatch repair defect.
On the basis of the subsequently collected tumor his-
tories, nine of the 15 patients with a high microsatellite
unstable sebaceous gland neoplasia were identi¢ed to
have Muir^Torre syndrome. In none of these cases,
however, were the clinical Amsterdam criteria for diag-
nosing hereditary nonpolyposis colorectal cancer ful-
¢lled. In the sebaceous tumors of the remaining six
patients, high microsatellite instability was an inciden-
tal ¢nding. In two of these six patients, single relatives
were known to be a¡ected with internal cancer; how-
ever, their family histories were not suggestive of
Muir^Torre syndrome or hereditary nonpolyposis col-
orectal cancer. In comparison with microsatellite in-
stability screening studies in a variety of other
randomly selected tumors, our study identi¢es seba-
ceous gland neoplasias as tumors with the highest fre-
quency of high microsatellite instability reported so
far, whereas sebaceous gland hyperplasia rarely exhibits
high microsatellite instability. Therefore, screening for
microsatellite instability in sebaceous gland neoplasias
will be of great value in the detection of an inherited
DNA mismatch repair defect, which predisposes to var-
ious types of internal cancers. Key words: DNA mismatch
repair/genomic instability/hereditary nonpolyposis colorectal
cancer/HNPCC/MSH2/MLH1/Muir^Torre syndrome/MTS/
cystic sebaceous tumor. J Invest Dermatol 120:858 ^864, 2003
S
ebaceous gland tumors are adnexal skin tumors, classi-
¢ed into the rare sebaceous gland neoplasias with their
subtypes sebaceous adenoma, epithelioma, and carcino-
ma and the frequently occurring sebaceous gland
hyperplasias.
The sebaceous gland neoplasia is the cutaneous marker tumor
for the autosomal-dominant Muir^Torre syndrome (MTS)
(OMIM #158320). MTS is de¢ned by the combination of at
least one sebaceous gland neoplasia and one internal malignancy
(Schwartz and Torre, 1995). In addition, keratoacanthomas and
sebaceous gland hyperplasias are a frequent ¢nding in MTS
patients. In contrast to sebaceous gland neoplasias, however,
neither solitary keratoacanthomas nor sebaceous hyperplasias are
skin tumors that point to MTS. MTS is known to be a phenoty-
pic variant of hereditary nonpolyposis colorectal cancer
(HNPCC, Lynch syndrome) (OMIM #120435 and #120436).
Because of the predisposition to cancers of various tissues (espe-
cially colon, urothelium, and endometrium), a life-long cancer
surveillance program has to be recommended both to an indivi-
dual a¡ected with MTS and his/her relatives.
Most typical skin tumors of MTS patients exhibit high micro-
satellite instability (MSI-H) (Honchel et al, 1994). MSI-H results
from a defective DNA mismatch repair (MMR) system (Alvino
et al, 2002) and has been shown to be the key feature of tumors
related to HNPCC. In patients with HNPCC as well as with
MTS, MSI in tumor tissue is caused by an underlying germline
mutation in a DNA MMR gene (Fishel et al, 1993; Bronner et al,
1994; Kolodner et al, 1994; Kruse et al, 1996; Lynch et al, 1999;
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Swale et al, 1999). In the tumor-prone tissue from such predis-
posed patients, however, the accumulation of replication errors
leading to MSI does not develop until somatic inactivation of
the corresponding second MMR allele (‘‘second hit’’) has taken
place (Kruse et al, 2001).
Earlier studies have shown that about two-thirds of patients
with the characteristic MuirTorre phenotype ‘‘sebaceous gland
tumor plus colorectal cancer’’ as well as the majority of patients
with even isolated cystic type sebaceous tumors (CST) harbor in-
herited DNA MMR defects (Kruse et al, 1998; 1999; Rˇtten et al,
1999).These ¢ndings are of clinical relevance as every clinical sign
that enables the detection of an inherited cancer predisposition
such as HNPCC is of considerable value for cancer prevention
(Lynch and Fusaro, 1999).
So far, extensive MSI screening studies of randomly selected
tumors of the HNPCC spectrum were focused on colorectal car-
cinomas (Aaltonen et al, 1998; Furlan et al, 1998; Cunningham
et al, 2001). Screening studies for MSI in skin tumors have only
been performed in keratoacanthomas (Halling et al, 1995; Peris
et al, 1997a; Langenbach et al, 1999) and skin tumors obviously
not related to the spectrum of HNPCC or MTS, such as malig-
nant melanomas (Peris et al, 1995; Quinn et al, 1995; Richetta et al,
1997; Talwalkar et al, 1998; Hussein et al, 2001), nevi (Hussein et al,
2001), conventional basal cell carcinomas, squamous cell carcino-
mas, and Bowen’s disease (Quinn et al, 1995). Until now, no MSI
screening study on unselected sebaceous gland tumors has been
published.
The goal of this study was therefore to determine the fre-
quency of MSI-H in a sample of randomly selected sebaceous
gland tumors and to correlate these data with the general tumor
history of the patient and his/her family. The results of this study
will give a ¢rst insight into the value of routine MSI assessment
in sebaceous gland tumors in view of surveillance recommenda-
tions and cancer prevention for patients at high risk for internal
malignancies.
MATERIALS AND METHODS
Patients and tumor samples Fifty-eight para⁄n-embedded sebaceous
gland tumors from 58 di¡erent Caucasian patients from Germany (‘‘ST’’
by RK, AR) and Italy (‘‘SSG’’ by MB) were consecutively selected, solely
on the basis of histopathology without the knowledge of the patient’s or
his/her family’s tumor history. The tumor sample comprised 25 sebaceous
gland neoplasias (six sebaceous adenomas, 16 sebaceous epitheliomas, three
sebaceous carcinomas) and 32 sebaceous gland hyperplasias.
Tumor histories of the patients and their relatives were subsequently
collected, independent of the inclusion of the sebaceous tumors in the
study. Sex and age of the patient, histopathology and localization of the
sebaceous tumor, as well as the tumor history are given inTable I.
All patients had given signed informed consent to the study. The study
was approved by the ethical committee of the Medical Faculty, University
of Duesseldorf, Germany, and the ethical committee of the ‘‘Casa Sollievo
della So¡erenza’’ Hospital in S. Giovanni Rotondo (Foggia), Italy,
respectively.
Histopathologic classi¢cation of sebaceous gland tumors Sebaceous
tumors were subclassi¢ed according to the following criteria. A sebaceous
hyperplasia was diagnosed if four or more mature sebaceous lobules were
attached to the infundibulum of a pilosebaceous follicle connected to the
overlying epidermis. Criteria for sebaceous adenomas were well-de¢ned
and enlarged sebaceous lobules comprising fully mature sebocytes,
frequently demonstrating an attachment to the epidermis with epidermal
thinning (Wick et al, 1997). A diagnosis of sebaceous epithelioma
(synonymous to sebaceoma) was made when more than half of the cells
were undi¡erentiated basaloid cells with rare nuclear atypia in the
presence of signi¢cant aggregates of sebaceous and transitional cells (Ueda
et al, 1999). Sebaceous epithelioma is not organized in well-demarcated
sebaceous lobules. The diagnosis of sebaceous epithelioma has been
rendered by two experienced dermatopathologists using well-established
morphologic criteria to di¡erentiate these neoplasms from basal cell
carcinomas (Ste¡en and Ackerman, 1994). Sebaceous carcinomas are
characterized by variable atypical polyhedral cells, separated from one
another by ¢brovascular stroma, sometimes with pagetoid spread of
atypical epithelial cells to the epidermis (Wick et al, 1997). Cystic
sebaceous tumors were de¢ned as large, well-circumscribed cystic
sebaceous lesions located deep in the dermis (Rˇtten et al, 1999).
Molecular genetic investigations
Isolation of genomic DNA Tumor DNAwas extracted from microdissected
para⁄n-embedded tumor tissue using the QIAamp tissue kit (QIAGEN,
Hilden, Germany). In 47 of the 58 patients, normal DNA was extracted
either from surrounding normal tissue with the QIAamp tissue kit or from
ethylenediamine tetraacetic acid anticoagulated peripheral blood samples
by the salting out procedure (Miller et al, 1988). In 11 patients, neither nor-
mal tissue nor blood for extracting normal DNAwas available.
Assessment of MSI in sebaceous gland tumors Except for the recommenda-
tions of the International Collaborative Group on HNPCC (ICG-
HNPCC; Loukola et al, 2001), there is no unanimity regarding the question
as to which microsatellite markers are required for diagnosing MSI. In the
case of available normal DNA, two alternative sets of ¢ve microsatellite
markers were generally used at the same time to analyze paired tumor and
normal DNA for assessing MSI. The ¢rst set comprises the so-called
Bethesda markers BAT25, BAT26, D2S123, D5S346, and D17S250, which
are recommended by the ICG-HNPCC.The second set, which was used in
the case of unclear MSI results after testing with the ¢rst set, comprises the
markers BAT40, D3S1298, D3S1611, D6S470, and D18S69. Microsatellite
markers were ampli¢ed by a polymerase chain reaction (PCR), using the
primer pairs described in Table II. One oligonucleotide of each pair of
primers was labeled with ABI £uorescence dye (Applied Biosystems,
Weiterstadt, Germany). To improve speci¢city, the PCR for each marker
was performed as a manual hot-start and touchdown PCR according to
standard protocols. In detail, the PCR was performed in a volume of
25 ml containing 4 ml (E80 ng) genomic DNA, 0.05 mM of each primer,
50 mM of each dNTP, 2.5 ml PCR bu¡er, 1.5 mM MgCl2, and 1.0 U Taq
polymerase (Gibco, Karlsruhe, Germany). Reactions were performed in
PCR tubes (Biozym Diagnostik, Hessisch Oldendorf, Germany) by means
of a T3 Thermocycler (Biometra, Goettingen, Germany) and consisted of
an initial step at 941C for 15 min, followed by 15 cycles of denaturation
at 941C for 45 s, annealing at primer-dependent temperature T1 (see
Table II) for 45 s, elongation at 721C for 60 s, and a subsequent 30 cycles
of denaturation at 941C for 45 s, annealing at primer-dependent tempera-
ture T2 (see Table II) for 45 s, elongation at 721C for 60 s. The ¢nal step
consisted of an additional elongation step at 721C for 10 min.Whenever
possible, after ampli¢cation 2^4 ml of each reaction of the ¢ve microsatel-
lite markers were pooled. PCR products were separated by electrophoresis
on an ABI Prism 310TM Genetic Analyzer (Applied Biosystems). The PCR
products of the pooled microsatellite markers were detected by di¡erent
£uorescence labeling (HEX, TET, or FAM) and the di¡erent size of the
corresponding microsatellite markers. GeneScan Analysis software
(Applied Biosystems) was used to size the PCR products and to analyze
the data. MSI is characterized by a length variation of microsatellites in
tumor DNA in comparison to normal DNA, and was thus detected as
allelic mobility shifts (see Fig 1). A tumor was de¢ned to exhibit MSI-H
if additional alleles were observed with two or more markers (Boland et al,
1998) and with at least 30% of all markers tested; a tumor was de¢ned to
exhibit microsatellite stability if none of all the markers examined (at least
¢ve) showed additional alleles.
If no normal DNAwas available, only the microsatellite marker BAT26
was used for assessing MSI. This method is based on the observation that
BAT26, a mononucleotide repeat microsatellite, is quasi-monomorphic in
DNA from normal individuals and MSI-negative samples, but shows im-
portant size variations in MSI-positive samples (Hoang et al, 1997). The ef-
¢ciency of BAT26 as the only microsatellite marker for the detection of
MSI in internal tumors has been evaluated in various studies (Iacopetta
and Hamelin, 1998; Zhou et al, 1998; Loukola et al, 2001). Zhou et al (1998)
showed that BAT26 could identify the MSI status of tumors from various
origins with 99.5% e⁄ciency in a single-step experiment without the re-
quirement for matching normal DNA. According to the results of Loukola
et al (2001), a tumor was de¢ned to exhibit MSI-H if BAT26 showed an
allele shift of three or more base pairs.
RESULTS
An unselected prospective series of 58 sebaceous tumors from dif-
ferent unrelated Caucasian patients was collected in Germany and
Italy. The series included 25 sebaceous gland neoplasias (compris-
ing six sebaceous adenomas, 16 sebaceous epitheliomas, and three
sebaceous carcinomas) and 32 sebaceous gland hyperplasias.
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Table I. Systematic study of consecutively collected sebaceous tumors: MSI data and clinical ¢ndings
(listed by sebaceous tumor histology)
Patient
(Sex)
Tumor histology
(Localization;
age at diagnosis)
MSI (markers with
additional alleles/examined
markers)
Tumor history
(patient and family)
ST-05 (M) SA (Forehead, 75 y) MSI-H (2/3) Patient: three basal cell carcinomas (7475 y)
ST-09 (M) SA (CST) (Forearm, 48 y) MSI-H (3/4) Patient: MuirTorre syndrome: carcinoma of ascending colon (35 y)
Family: colorectal carcinoma (brother of father with 72 y)
ST-10 (M) SA (CST) (Shoulder, 79 y) MSI-H (3/3) Patient: MuirTorre syndrome: colorectal carcinoma (72 y)
Family: no tumors
ST-15 (M) SA (CST) (Forehead, 57 y) MSI-H (3/8) Patient: no further tumors
Family: carcinoma of the gallbladder (mother with 84 y), hepatic
carcinoma (sister of the mother with 72 y)
SSG-20 (M) SA (Face, 74 y) MSS (B26) Patient and family: no further tumors
SSG-50 (M) SA (Nose, 69 y) MSS (B26) Patient and family: no further tumors
ST-03 (F) SE (Capillitium, 60 y) MSS (0/7) Patient: no further tumors
Family: cancer of the bone (father), lung cancer (sister of mother),
colorectal carcinoma (grandmother (m))
ST-08 (M) SE (Nose, 73 y) MSS (0/6) Patient and family: no further tumors
ST-11 (M) SE (Upper arm, 55 y) MSS (B26) Patient and family: no further tumors
ST-12 (F) SE (Shoulder, 88 y) MSS (0/7) Patient: basal cell carcinoma with 88 y
Family: unknown cancer of the lower abdomen (daughter)
ST-13 (F) SE (Upper lip, 83 y) MSS (0/6) Patient: no further tumors
Family: colorectal carcinoma (grandfather with 80 y)
ST-17 (M) SE (Forehead, 65 y) MSS (0/5) Patient and family: no further tumors
ST-21 (F) SE (Forehead, 79 y) MSI-H (B26þ) Patient and family: no further tumors
ST-23 (M) SE (Back, 66 y) MSI-H (6/7) Patient: malignant melanoma (31y), brain metastases of a malignant
melanoma (46 y), three extrafacial basal cell carcinomas (63 y)
Family: basal cell carcinoma (son with 30 y)
ST-24 (M) SE (Thigh, 61y) MSI-H (6/6) Patient and family: no further tumors
ST-26 (F) SE (Neck, 76 y) MSI-H (4/9) Patient: MuirTorre syndrome: colorectal carcinoma (42 y) and breast
cancer (68 y)
Family: no tumors
ST-28 (F) SE (Root of the nose, 65 y) MSI-H (3/3) Patient: MuirTorre syndrome: endometrial carcinoma, cancer of the
ureter (60 y), bladder cancer (63 y), squamous cell carcinoma of the
skin and malignant melanoma (65 y)
Family: colorectal carcinoma (mother 78 y), bladder cancer (sister of
the mother 80 y)
ST-33 (M) SE (Forehead, 64 y) MSI-H (2/6) Patient: MuirTorre syndrome: colorectal carcinoma (54 y)
Family: colorectal carcinomas (mother and sister of the mother 48 y),
cancer of the lower abdomen (mother 53 y)
ST-34 (M) SE (Root of the nose, 86 y) MSI-H (4/6) Patient: no further tumors
Family: colorectal carcinoma (father)
ST-36 (F) SE (Nose, 88 y) MSS (0/6) Patient: basal cell carcinoma
ST-39 (F) SE (Neck, 78 y) MSI-H (3/3) Patient: MuirTorre syndrome: colorectal carcinoma (48 y), cancer of the
lower abdomen (67 y) and a further sebaceous epithelioma (78 y)
Family: cancer of the lower abdomen (mother 48 y), lung cancer
(uncle 45 y), leukemia (grandson 17 y)
ST-41 (M) SE (Cheek, 81y) MSI-H (2/2) Patient: MuirTorre syndrome: colon cancer (94 y), basal cell
carcinoma (81y)
Family: no tumors
ST-27 (M) SC (Back, 63 y) MSI-H (2/2) Patient: MuirTorre syndrome: carcinoma of ascending colon (60 y)
Family: no tumors
ST-31 (F) SC (Back, 71y) MSI-H (3/4) Patient: MuirTorre syndrome: colorectal carcinoma, bladder cancer and
basal cell carcinoma
Family: colorectal carcinoma (brother), colorectal carcinoma,
endometrial carcinoma, laryngeal carcinoma, cancer of the stomach
(mother, sisters of the mother and their children)
SSG-21 (F) SC (Face, 85 y) MSS (0/5) Patient and family: no further tumors
ST-01 (M) SH (Cheek, 65 y) MSS (0/5) Patient and family: no further tumors
ST-02 (M) SH (Cheek, 48 y) MSS (0/5) Patient and family: no further tumors
ST-04 (M) SH MSS (B26) Patient: no further tumors
Family: malignant melanoma (brother of the mother with 40 y)
ST-07 (M) SH (Cheek, 44 y) MSS (B26) Patient and family: no further tumors
ST-14 (M) SH (Root of the nose, 65 y) MSS (B26) Patient and family: no further tumors
ST-16 (M) SH (Forehead, 47 y) MSS (B26) Patient and family: no further tumors
ST-18 (M) SH (Cheek, 64 y) MSS (0/6) Patient and family: no further tumors
ST-20 (F) SH (Chest, 60 y) MSS (0/6) Patient: no further tumors
Family: colorectal cancer (father with 61y)
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Molecular genetic analyses with microsatellite markers showed
that 60% (15 of 25) of the sebaceous gland neoplasias exhibited
MSI-H, pointing towards an underlying DNA MMR defect,
whereas only one of the 32 sebaceous gland hyperplasias was
highly unstable. The proportion of MSI-H sebaceous gland neo-
plasias was almost equally distributed between the sebaceous
gland adenomas, epitheliomas, and carcinomas (for details see
Tables III, I).Within the sebaceous neoplasias all three CST ex-
hibited MSI-H.
In a second step, the patients were contacted for their own and
their family’s history. On the basis of the subsequently collected
tumor histories, nine of the 15 patients with MSI-H sebaceous
gland neoplasia proved to be a¡ected with at least one additional
internal cancer and were therefore diagnosed to have MTS. The
clinical Amsterdam criteria for diagnosing HNPCC, (Vasen et al,
1991), however were not ful¢lled in any of these patients. In the
sebaceous tumors of the other six patients, MSI-H was an inci-
dental ¢nding, meaning that no internal cancer typical for MTS
ST-22 (F) SH (Cheek, 52 y) MSS (0/5) Patient: no further tumors
Family: cancer of the gallbladder (sister of the mother)
ST-25 (F) SH (Cheek, 78 y) MSS (0/6) Patient: benign colon tumor (52 y)
Family: no further tumors
ST-30 (M) SH (Infraorbital, 53 y) MSS (0/6) Patient: cyst of the hair follicle at 53 y
Family: cancer of the stomach (father, mother, and grandmother (m)),
breast cancer (mother)
ST-35 (F) SH (Forehead, 77 y) MSS (0/6) Patient and family: no further tumors
ST-38 (M) SH (Cheek, 46 y) MSS (0/6) Patient: no further tumors
Family: malignant brain tumor (mother with460 y)
ST-42 (F) SH (Cheek, 73 y) MSS (0/5) Patient: no further tumors
Family: cancer of the stomach (father)
SSG-01 (M) SH (Face, 56 y) MSI-H (3/5) Patient: urothelial papilloma
Family: colon adenoma (brother), prostate carcinoma (two brothers),
CRC and breast cancer (mother and sister), esophageal carcinoma
(grandmother (m)), basal cell carcinoma (father), lung cancer
(father’s sister), prostate carcinoma (mother’s brother), breast cancer
(sister), cancer of the ovary (sister)
SSG-02 (M) SH (Face, 61y) MSS (0/5) Patient: no further tumors
Family: ‘‘abdominal malignoma’’ (mother)
SSG-03 (M) SH (Face, 67 y) MSS (0/6) Patient: squamous cell carcinoma
Family: ‘‘skin tumor’’ (father)
SSG-04 (M) SH (Face, 60 y) MSS (0/5) Patient: prostate carcinoma
Family: no tumors
SSG-07 (M) SH (Face, 60 y) MSS (0/5) Patient and family: no further tumors
SSG-08 (F) SH (Face, 76 y) MSS (0/5) Patient: tubular colonic adenoma
Family: prostate carcinoma (brother)
SSG-10 (M) SH (Face, 62 y) MSS (0/6) Patient: malignant melanoma
SSG-11 (M) SH (Face, 58 y) MSS (0/6) Patient: no further tumors
Family: cancer of the tongue (father), cancer of unknown primary
(mother)
SSG-12 (F) SH (Mons pubis) MSS (0/6) Patient: no further tumors
Family: colorectal carcinoma (father’s brother)
SSG-13 (M) SH (Face, 44 y) MSS (0/5) Patient: no further tumors
Family: lung cancer (father)
SSG-14 (M) SH (Face, 35 y) MSS (0/5) Patient: no further tumors
Family: malignant astrocytoma (father), testicular cancer (brother)
SSG-15 (F) SH (Face, 61y) MSS (0/5) Patient: no further tumors
Family: laryngeal carcinoma (brother), uterine leiomyoma (daughter)
SSG-16 (M) SH (Face, 63 y) MSS (0/5) Patient and family: no further tumors
SSG-17 (M) SH (Capillitium, 63 y) MSS (B26) Patient: two basal cell carcinomas
Family: no further tumors
SSG-18 (M) SH (Face, 78 y) MSS (0/5) Patient: no further tumors
Family: colorectal cancer and lung cancer (father)
SSG-49 (M) SH (Face, 64 y) MSS (0/5) Patient and family: no further tumors
SSG-55 (F) SH (Cheek, 66 y) MSS (B26) Patient: breast cancer, basal cell carcinoma
Family: cancer of the stomach (father)
SSG-59 SH (Face) MSS (0/5) Patient: basal cell carcinoma
Family: adenocarcinoma of the stomach (father)
ST, sebaceous tumors from Germany; SSG, sebaceous tumors from Italy; SH, sebaceous hyperplasia; SA, sebaceous adenoma; SE, sebaceous epithelioma; SC, sebaceous
carcinoma; M, male; F, female; CRC, Colorectal carcinoma; B26þ , allele shift of 3 bp or more with the single marker BAT26; B26, no allele shift with the single
marker BAT26; MSI-H, high microsatellite instability (a tumor that shows additional alleles with two or more microsatellite markers and with at least 30% of all markers
tested or an allele shift of 3 bp or more with the single marker BAT26): MSS, microsatellite stability (a tumor that shows no additional alleles with at least ¢ve micro-
satellite markers examined or no allele shift with the single microsatellite marker BAT26); m, matrilineal; f, patrilineal.
Table I. Continued
Patient
(Sex)
Tumor histology
(Localization;
age at diagnosis)
MSI (markers with
additional alleles/examined
markers)
Tumor history
(patient and family)
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or HNPCC had occurred together with the sebaceous tumor. In
two of these six patients (ST-15 and ST-34), single relatives had a
history of internal cancer; however, their family histories did not
meet the clinical criteria for HNPCC.
The patient with the MSI-H sebaceous hyperplasia also had
a benign internal tumor (urothelial papilloma). Several of his
relatives have been diagnosed with cancer of di¡erent organs
suspicious for HNPCC.
DISCUSSION
In this study, for the ¢rst time we assessed the incidence of MSI-
H in a consecutive series of randomly selected sebaceous gland
neoplasias and hyperplasias. In our study, 60% of patients with a
sebaceous gland neoplasia exhibited MSI-H and are thus at risk
for an underlying inherited DNA MMR defect. Alternatively,
MSI-H could be caused by a somatic inactivation of both alleles
of a DNA MMR gene. It has to be considered, however, that at
least two-thirds of MTS patients with MSI-H sebaceous tumors
harbor a germline mutation in one of the DNA MMR genes
MSH2 or MLH1 (Kruse et al, 1998). The age at diagnosis proved
to be lower in sebaceous gland neoplasias with MSI-H (E70 y)
than in neoplasias with microsatellite stability (E74 y). This is
compatible with the observation that the associated neoplasms in
hereditary cancer syndromes such as HNPCC and MTS on aver-
age develop earlier than their sporadic counterparts. Interestingly,
mean age at diagnosis of MSI-H sebaceous gland neoplasias
proved to be signi¢cantly higher than that of the initial sebaceous
neoplasias in the 120 MTS patients reviewed by Cohen et al (1991)
Figure1. MSI in sebaceous tumors.The electropherograms of PCR-ampli¢ed microsatellite markers from normal DNA and from tumor DNA. (a), (b)
Sebaceous epithelioma from patient ST-23: microsatellite markers D17S250 and D2S123 show additional alleles in tumor DNA (arrows). (c) Sebaceous
adenoma from patient ST-10: microsatellite marker BAT26 shows a shift of 3 bp in tumor DNA. (d) Sebaceous epithelioma from patient ST-21: micro-
satellite marker BAT26 shows a shift of at least 5 bp in tumor DNA.
Table II. Microsatellite markers: primer sequences (50-30) and their annealing temperatures for
microsatellite markers used to assess MSI
Marker (£uorescence labeling) Forward primer Reverse primer
Annealing temperature T1-T2
(touchdown PCR)
BAT25 (HEX) F-tcgcctccaagaatgtaagt R-tctgcattttaactatggctc 581C-541C
BAT26 (TET) F-tgactacttttgacttcagcc R-aaccattcaacatttttaaccc 561C-521C
D2S123 (FAM) F-aaacaggatgcctgccttta R-ggactttccacctatgggac 621C-581C
D5S346 (FAM) F-actcactctagtgataaatcg R-agcagataagacagtattactagtt 621C-581C
D17S250 (TET) F-ggaagaatcaaatagacaat R-gctggccatatatatatttaaacc 561C-521C
BAT40 (TET) F-attaacttcctacaccacaac R-gtagagcaagaccaccttg 601C-561C
D3S1298 (TET) F-agctctcagtgccacccc R-gaaaaatcccctgtgaagcg 611C-571C
D3S1611 (FAM) F-gcctagcaagatgacttctaag R-agctgagactacaggcatttg 621C-581C
D6S470 (HEX) F-aagcgatctcaccatatacac R-acactgcaaaacgattacca 601C-561C
D18S69 (FAM) F-ctctttctctgactctgacc R-gactttctaagttcttgccag 601C-561C
Table III. Results on MSI assessment in sebaceous tumors
from di¡erent patients
Tumor histology MSI-H tumors /total number
Sebaceous neoplasias 15/25 (60%)
Sebaceous adenomas 4/6 (67%)
Sebaceous epitheliomas 9/16 (56%)
Sebaceous carcinomas 2/3 (67%)
Sebaceous hyperplasias 1/32 (3%)
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(53 y). This discrepancy may be due to the unselected recruitment
of sebaceous tumors in this study. All four CSTs within our new-
ly collected sebaceous tumors exhibited MSI-H. In our previous
studies (Kruse et al, 1998; 1999; Rˇtten et al, 1999), each of 10 CSTs
examined for MSI showed MSI-H. Thus, our results support the
hypothesis that the CST may be a speci¢c marker tumor for an
underlying DNA MMR defect.
In addition to the examination of sebaceous gland neoplasias,
we also looked for MSI in a series of sebaceous gland hyperpla-
sias. In comparison to sebaceous gland neoplasias, only 3% of the
hyperplasias exhibited MSI-H. This result is consistent with the
clinical observation that the frequently occurring sebaceous hy-
perplasia is not a diagnostic criterion for MTS (Schwartz and
Torre, 1995).
In contrast to randomly selected sebaceous neoplasias, almost
100% of sebaceous tumors from patients with colorectal carcino-
mas as part of their underlying MTS (Honchel et al, 1994; Peris
et al, 1997b; Kruse et al, 1998; Lynch et al, 1999; Ueda et al, 1999;
Entius et al, 2000) or HNPCC (Swale et al, 1999), as well as almost
100% of CSTs (Kruse et al, 1999; Rˇtten et al, 1999), are known to
exhibit MSI. In the study by Harwood et al (2001), MSI was de-
monstrated in three of six sporadic sebaceous carcinomas from
immunosuppressed organ transplant patients. The authors hy-
pothesized that immunosuppression might unmask a previously
silent MTS phenotype in some cases.
The assessment of MSI in colorectal tumors has been demon-
strated to be a useful screening method to identify persons at
high risk for HNPCC (Lamberti et al, 1999). Accordingly, sys-
tematic screening studies in HNPCC-related internal tumors to
detect underlying DNA MMR defects have been mainly per-
formed with unselected colorectal carcinomas. These studies re-
vealed MSI-H in 12% (Aaltonen et al, 1998), 9% (Furlan et al,
1998), or 20% (Cunningham et al, 2001) of colorectal carcinomas.
Loukola et al (1999) designed a study to assess the feasibility of
screening benign colorectal adenoma patients for HNPCC.
Among these adenoma patients, only 1.6% had at least one MSI
adenoma. In endometrial carcinomas, MSI was detected in about
28% of cases (12 of 42) (Catasus et al, 1998). These frequencies are
signi¢cantly lower than the MSI-H frequency of 60% in our ser-
ies of sebaceous gland neoplasias.
So far, screening studies for MSI in randomly selected nonse-
baceous skin tumors have only been performed with keratoa-
canthomas (Halling et al, 1995; Peris et al, 1997a; Langenbach et al,
1999) and tumors not related to HNPCC or MTS, such as malig-
nant melanomas (Peris et al, 1995; Quinn et al, 1995; Richetta et al,
1997; Talwalkar et al, 1998; Hussein et al, 2001), nevi (Hussein et al,
2001), basal cell carcinomas, squamous cell carcinomas, and
Bowen’s disease (Quinn et al, 1995). The MSI-H detection rates in
these skin tumors were in the range of only 0%^11% (for details
seeTable IV).
In conclusion, this is the ¢rst systematic MSI screening study
in sebaceous tumors selected solely on the basis of their histo-
pathologic diagnosis without previous knowledge of the patients’
and their family’s history for internal tumors. As more than half
of the randomly selected sebaceous neoplasias showed MSI-H,
our study demonstrates the clinical relevance of the histopatholo-
gic diagnosis and the MSI assessment of a sebaceous gland neo-
plasia in terms of early detection of patients (and families) at high
risk for internal cancer.
The assessment of MSI in a sebaceous gland neoplasia is there-
fore highly relevant for cancer prevention. For all MTS and
HNPCC patients, as well as for patients with MSI-H sebaceous
gland tumors and relatives with internal cancer that do not meet
the HNPCC criteria but belong to the MTS/HNPCC spectrum
(e.g., ST-15 or ST-34), we recommend the same regular cancer
surveillance program according to the guidelines of the ICG-
HNPCC. This is also recommended for the ¢rst-degree relatives
of these patients.
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